Moleculin Biotech’s (MBRX) “Buy” Rating Reaffirmed at HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $22.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

Moleculin Biotech Trading Up 0.7%

NASDAQ:MBRX traded up $0.02 during midday trading on Tuesday, hitting $2.12. 12,259 shares of the company traded hands, compared to its average volume of 174,417. The firm’s fifty day moving average is $3.37 and its 200-day moving average is $6.99. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $33.00. The firm has a market capitalization of $4.31 million, a P/E ratio of -0.06 and a beta of 1.73.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.